Section
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
A large-scale study using UK Biobank data reveals that adhering to a Planetary Health Diet significantly lowers the risk of chronic kidney disease, emphasizing the dual benefits of plant-forward, sustainable eating for both personal health
A large-scale multi-cohort study involving nearly 190,000 participants reveals that the EAT-Lancet reference diet, measured by the Planetary Health Diet Index, reduces the risk of incident chronic kidney disease, particularly among women, a
Recent research from the UK Biobank reveals that a sustainable, plant-forward diet can lower chronic kidney disease risk by 26%, offering a dual solution for environmental and personal health.
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease
The Navigate-Kidney trial demonstrates that community health worker support significantly improves interdialytic weight gain, dialysis adherence, and patient activation among Hispanic and Latino individuals on hemodialysis, addressing criti
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization ce
A large-scale multicenter study reveals that 46.6% of severe AKI survivors in India and Southeast Asia experience major adverse kidney events (MAKE) within two years, with mortality and new-onset chronic kidney disease being the primary dri
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk
A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP
This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantl
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu
A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.
